30
views
0
recommends
+1 Recommend
1 collections
    0
    shares
      • Record: found
      • Abstract: not found
      • Article: not found

      A SARS-CoV-2 omicron (B.1.1.529) variant outbreak in a primary school in Geneva, Switzerland

      letter

      Read this article at

      ScienceOpenPublisherPMC
      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The role of primary-school children in community circulation of SARS-CoV-2 remains unclear, 1 and this is particularly true for the highly transmissible omicron (B.1.1.529) variant, which has a high potential for immune escape, increasing the likelihood to infect or reinfect vaccinated family members. 2 We investigated a SARS-CoV-2 outbreak in a primary school in Geneva, Switzerland, as part of a longitudinal, prospective, school class-based surveillance study (SEROCoV-Schools). 3 Detailed methods are in the appendix (pp 1–2). Briefly, children (aged 3–7 years), teachers, and school staff from four classes in the primary school (classes A–D) were invited to participate in the surveillance study. When a participant tested positive, we prospectively investigated the transmission of SARS-CoV-2 in the school and in the household. The first case (class C) of SARS-CoV-2 infection with the omicron variant was notified to our team on Jan 11, 2022, which was the day after the start of the school term after the winter vacation, referred to as day 0. Children and staff members were tested for SARS-CoV-2 infection via RT-PCR on oropharyngeal swabs twice by our team, on day 3 and day 7, regardless of symptoms (appendix p 3). Additional tests were done on a few participants who developed symptoms after day 7. Within 3 days of identification of the first case, we identified cases in all four classes being investigated. Cumulative infection incidence was four (33%) of 12 children in class A (which increased to five [42%] of 12 if including a probable case, as defined in the appendix [p 1]), two (15%) of 13 in class B, nine (56%) of 16 in class C, and 11 (61%) of 18 in class D. At the time of the study, only two children were vaccinated against COVID-19 with one dose; both tested positive for SARS-CoV-2 infection. Because this outbreak investigation is part of a surveillance study that began on Oct 5, 2021, we were able to determine that 19 (29%) of 66 children (four to six children in each class) had anti-spike SARS-CoV-2 IgG antibodies (unrelated to vaccination) or PCR-confirmed infection, or both, before the beginning of the omicron outbreak in January, 2022. Among those, 17 were tested during the outbreak and five (29%) of 17 were infected. Among the children without indication of previous infection or vaccination who were tested, 20 (50%) of 40 were infected. Five (50%) of ten teachers and one (20%) of five non-teaching staff members at the school tested positive during the omicron outbreak. Two (13%) of 15 staff members were not vaccinated against COVID-19, and both tested positive. We also investigated the introduction of SARS-CoV-2 infections in 24 households of children who tested positive. 52 household members were tested once or twice within the week after their child or sibling tested positive (appendix p 3). Infections with the SARS-CoV-2 omicron variant were found in 15 (63%) of 24 households and 25 (48%) of 52 investigated household members (which increased to 27 [50%] of 54 if including probably cases), a household cumulative infection incidence that was similar to the findings of another report from South Korea. 4 42 (91%) of 46 parents included were vaccinated, of whom 32 (76%) had received a booster. After excluding those who tested positive just before the outbreak and those who were not tested, the cumulative incidence of infection among those who had received a booster vaccination was 13 (43%) of 30, among those who had received one or two doses of vaccine was two (33%) of six, and among those who were unvaccinated was two (67%) of three, supporting the idea that this variant is highly transmissible even among fully vaccinated people. 5 Most infections were symptomatic, with 25 (81%) of 31 children and siblings and 19 (86%) of 22 adults (parents, teachers, and non-teaching staff members combined) reporting symptoms. Four (100%) of four adults who were unvaccinated, three (75%) of four adults who were vaccinated with one or two doses, and 12 (92%) of 13 who were vaccinated with two or three doses reported symptoms. No hospitalisations were reported. Several factors probably led to this large outbreak, including close contacts between children at school, several separate introductions (as suggested by contact tracing) after the winter vacation in a context of high weekly incidence (3101 of 100 000 inhabitants in Geneva at the end of week 2 of 2022 were infected, of which >96% were caused by the omicron variant), reinfections with the omicron variant, 6 and isolation periods shortened to 5 days from Jan 13, 2022, by the health authorities, which led to potentially infectious participants being sent back to school. In summary, this prospective, school class-based study provides evidence of higher transmission of infections in school settings with the omicron variant than was reported with previous variants. 3 Children appear to be an important source of extra-household infections and have a key role in community transmission. This study was approved by the ethics committee of the Canton of Geneva (Project ID 2020-02957). All parents and teachers were informed about the study and gave written informed consent, while children gave verbal assent to participate. The SEROCoV-Schools study was supported by the Federal Office of Public Health, the Private Foundation of the Geneva University Hospitals, the Fondation des Grangettes, the Center for Emerging Viral Diseases, and a SNF NRP (National Research Program) 78 COVID-19 Grant 198412 (to SJM and IE). We declare no competing interests. SEROCoV-Schools Study Group members are listed in the appendix (p 5).

          Related collections

          Most cited references7

          • Record: found
          • Abstract: found
          • Article: found
          Is Open Access

          Rapid epidemic expansion of the SARS-CoV-2 Omicron variant in southern Africa

          The SARS-CoV-2 epidemic in southern Africa has been characterized by three distinct waves. The first was associated with a mix of SARS-CoV-2 lineages, while the second and third waves were driven by the Beta (B.1.351) and Delta (B.1.617.2) variants, respectively 1–3 . In November 2021, genomic surveillance teams in South Africa and Botswana detected a new SARS-CoV-2 variant associated with a rapid resurgence of infections in Gauteng province, South Africa. Within three days of the first genome being uploaded, it was designated a variant of concern (Omicron, B.1.1.529) by the World Health Organization and, within three weeks, had been identified in 87 countries. The Omicron variant is exceptional for carrying over 30 mutations in the spike glycoprotein, which are predicted to influence antibody neutralization and spike function 4 . Here we describe the genomic profile and early transmission dynamics of Omicron, highlighting the rapid spread in regions with high levels of population immunity.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: found
            Is Open Access

            Outbreak caused by the SARS-CoV-2 Omicron variant in Norway, November to December 2021

            In late November 2021, an outbreak of Omicron SARS-CoV-2 following a Christmas party with 117 attendees was detected in Oslo, Norway. We observed an attack rate of 74% and most cases developed symptoms. As at 13 December, none have been hospitalised. Most participants were 30–50 years old. Ninety-six percent of them were fully vaccinated. These findings corroborate reports that the Omicron variant may be more transmissible, and that vaccination may be less effective in preventing infection compared with Delta.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: found
              Is Open Access

              Omicron variant susceptibility to neutralizing antibodies induced in children by natural SARS-CoV-2 infection or COVID-19 vaccine

              ABSTRACT The novel SARS-CoV-2 Omicron variant may increase the risk of re-infection and vaccine breakthrough infections as it possesses key mutations in the spike protein that affect neutralizing antibody response. Most studies on neutralization susceptibility were conducted using specimens from adult COVID-19 patients or vaccine recipients. However, since the paediatric population has an antibody response to SARS-CoV-2 infection that is distinct from the adult population, it is critical to assess the neutralization susceptibility of pediatric serum specimens. This study compared the neutralization susceptibility of serum specimens collected from 49 individuals of <18 years old, including 34 adolescent BNT162b2 (Pfizer-BioNTech) vaccine recipients, and 15 recovered COVID-19 patients aged between 2 and 17. We demonstrated that only 38.2% of BNT162b2 vaccine recipients and 26.7% of recovered COVID-19 patients had their serum neutralization titre at or above the detection threshold in our live virus microneutralization assay. Furthermore, the neutralizing antibody titer against the Omicron variant was substantially lower than those against the ancestral virus or the Beta variant. Our results suggest that vaccine recipients and COVID-19 patients in the pediatric age group will likely be more susceptible to vaccine breakthrough infections or reinfections due to the Omicron variant than previous variants.
                Bookmark

                Author and article information

                Journal
                Lancet Infect Dis
                Lancet Infect Dis
                The Lancet. Infectious Diseases
                Elsevier Ltd.
                1473-3099
                1474-4457
                14 April 2022
                14 April 2022
                Affiliations
                [a ]Unit of Population Epidemiology, Division of Primary Care Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland
                [b ]Laboratory of Virology, Department of Diagnostics, Geneva University Hospitals, 1205 Geneva, Switzerland
                [c ]Department of Pediatrics, Gynecology & Obstetrics, Pediatric Infectious Disease Unit, Geneva University Hospitals, 1205 Geneva, Switzerland
                [d ]Division of Primary Care Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland
                [e ]Division of Infectious Diseases, Department of Medicine, Geneva University Hospitals, 1205 Geneva, Switzerland
                [f ]Department of Microbiology and Molecular Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland
                [g ]Institute of Global Health, Faculty of Medicine, University of Geneva, Geneva, Switzerland
                [h ]Department of Health and Community Medicine, Faculty of Medicine, University of Geneva, Geneva, Switzerland
                [i ]Center for Emerging Viral Diseases, Geneva University Hospitals and University of Geneva, Geneva, Switzerland
                [j ]Institute of Bioengineering, School of Engineering, École Polytechnique Fédérale de Lausanne, Lausanne, Switzerland
                [k ]Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD, USA
                [l ]University Center for General Medicine and Public Health, University of Lausanne, Lausanne, Switzerland
                Article
                S1473-3099(22)00267-5
                10.1016/S1473-3099(22)00267-5
                9009838
                35429994
                8bef6b4b-950f-4459-a9a4-262c51ffbb2c
                © 2022 Elsevier Ltd. All rights reserved.

                Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.

                History
                Categories
                Correspondence

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article